INFLIXIMAB INFLIXIMAB (11399Y) Supply only until 01/07/2027 infliximab 100 mg injection, 1 vial 11399Y Body System: Antineoplastic And Immunomodulating Agents > Immunosuppressants > Immunosuppressants Manner of administration:Injection Private S100 HSD Private Authority Required Restriction Indication: Severe Crohn disease Treatment phase: Subsequent continuing treatment Quantities & Cost Max qty packs Max qty units # of repeats DPMQ Max safety net General Patient Charge Max qty packs: 1 Max qty units: 1 # of repeats: 0 DPMQ: $202.85 Max safety net: $25.00 General Patient Charge: $25.00 Available brands Inflectra Ixifi Remicade Remsima Renflexis
